We next performed side-by-side experiments comparing the changes in cell signaling caused by regorafenib, aramchol and the drugs combined in ATG16L1 T300/T300 and ATG16L1 A300/A300 HCT116 colorectal cancer cells and in HuH7 hepatoma cells (Supplementary Tables 1–4). Here, ATG16L1 is linked to colorectal cancer.